Darunavir/ritonavir (DRV/r) is a highly effective and well-tolerated protease inhibitor that has been used to treat people living with HIV (PLHIV) for over a decade. Though DRV/r has seen significant utilization in many high-income settings, this has not been the case in low- and middle-income countries (LMICs) despite DRV/r’s significant benefits. However, the recent development of a quality-assured FDC of DRV/r that is now available at a price below that of LPV/r paves the way for the uptake of DRV/r in LMICs to replace poorly tolerated medicines. We, as HIV community advocates representing over 40 organizations spanning 20 countries, demand that all global and national stakeholders rapidly adopt, procure, and introduce DRV/r so that those PLHIV that are poorly tolerating their medicines will finally have a path to a happier and healthier life.
Read the full statement here.
Source : AfroCAB
Related HIV and Co-Infections News
-
Infectious Disease Advisor: Real-world data support switch to doravirine-based ART: HIV-1 control and QOL
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.